People coming off weight-loss injections risk fast weight gain

A BMJ analysis of 37 trials (over 9,000 patients) finds GLP‑1 weight‑loss injections deliver large initial reductions (roughly 20% of body weight) but patients regained on average 0.8 kg/month after stopping—returning to pre‑treatment weight in about 18 months—versus ~0.1 kg/month after conventional dieting. Only eight trials specifically tested newer GLP‑1 drugs with at most one year of post‑treatment follow‑up, highlighting limited long‑term evidence; UK context includes ~1.6m private users in the past year and NHS prescribing constraints (Wegovy two‑year cap, no set limit for Mounjaro), implying policy and adherence dynamics that could influence long‑term revenue trajectories for makers such as Novo Nordisk and Eli Lilly.

Analysis

Market structure: Big-cap GLP-1 makers (NVO, LLY) and specialty injectable supply chains are clear winners because the data reinforces a chronic‑use narrative that supports recurring revenue and pricing power; private-pay demand (UK: ~1.6M users, 3.3M interested) implies a multi‑year uptake runway but creates payer/reimbursement constraints. Losers include one‑off diet programs, OTC slimming brands and smaller consumer-facing weight‑management services where churn and substitution risk rise. The supply/demand balance points to sustained demand with periodic supply squeezes—this should compress IG pharma credit spreads and raise NVO/LLY equity valuations while lifting equity implied vols around policy/regulatory news.

Risk assessment: Tail risks include rapid payer restrictions (e.g., limiting reimbursement to ≤2 years) or adverse long‑term safety signals that could cut lifetime revenue by >30% versus chronic‑use assumptions; manufacturing or supply disruptions create meaningful short‑term revenue shocks. Time horizons: immediate (days) — sentiment swings on headlines; short (3–6 months) — formulary/NICE/FDA/payer decisions; long (1–5 years) — outcome trials and real‑world persistence determine lifetime value. Hidden dependencies: physician prescribing limits, private vs NHS mix, and behavioral adherence (if <50% persist past 12 months revenue forecasts need downward revision).

Trade implications: Prefer large‑cap exposure with insurance against policy/regulatory churn: accumulate NVO (Novo Nordisk) 2–3% portfolio weight over the next 4–12 weeks, targeting +20–30% 12‑month upside if reimbursement stays permissive; hedge with a 9–12 month NVO 8–12% OTM put spread sized to cap downside at ~30% loss. Tactical pair: long NVO, short consumer weight‑management operator WW (WW) 0.5–1% — WW is exposed to demand substitution and likely margin pressure over 6–12 months. Expect option vols to spike on NICE/US payer announcements; use calendar call spreads if you want long exposure with limited theta decay.

Contrarian angles: Markets may underprice the chronic‑care framing that converts high up‑front sales into stable annuity cash flows (historical parallel: insulin/biologics), arguing for underweighting fears of one‑off churn. Conversely, consensus may overstate total addressable market — many interested consumers won’t qualify for prescriptions or will stop therapy after 12–24 months, so small/mid caps betting solely on mass adoption are overvalued. Watch real‑world persistence: if average refill rates fall below 50% at 12 months, downgrade growth forecasts and tighten longs.

Key Decisions for Investors

• Establish a 2–3% long position in NVO (Novo Nordisk) over next 4–12 weeks; scale in on pullbacks of 5–10%; target a 12‑month upside of 20–30% conditional on stable reimbursement and no major safety signals; take profits or reassess at +25–30% or if NICE/FDA limit duration.
• Hedge NVO position with a 9–12 month put spread (buy 1 12% OTM put, sell 1 20% OTM put) sized to limit portfolio downside to ~30% in a regulatory shock scenario; cost‑effective way to protect against payer restriction risk in next 6–12 months.
• Establish a 0.5–1% short (or buy puts) position in WW (Weight Watchers) as a relative loser to GLP‑1 adoption over 6–12 months; if WW weakens by >15% on earnings or guidance, add to short up to 1.5% total position.
• Monitor three specific catalysts in next 30–180 days and act: (1) UK NICE guidance or NHS policy changes (upgrade/downgrade positions within 48 hours of announcement), (2) US payer formulary/adoption disclosures quarterly, (3) any safety/outcome trial readouts—if refill/persistence <50% at 12 months, reduce NVO exposure by half.